Search

everythinglearnresearchcommunity

for

Search:↓

Hair transplants and hair loss treatments like oral Fin and Min are discussed, with some humor about public figures' hair. Missing a single day of these treatments typically has little impact, but longer gaps can affect results.

The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.

A user claims a product can treat alopecia, but others are skeptical, calling it a scam due to lack of evidence and transparency. The product is said to inhibit Type II 5-αr by 22.9%, but is considered weaker than existing DHT blockers.

Scientists discovered a new T cell treatment that could regrow hair. Users are skeptical but hopeful, with some relying on finasteride and minoxidil in the meantime.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

An 18-year-old with diffuse hair thinning is considering switching from a topical Minoxidil 10% + Finasteride 0.1% solution to Minoxidil 5% foam and oral Finasteride 0.5mg, while also addressing vitamin D deficiency and potential scalp inflammation. Users suggest using Nizoral shampoo for inflammation, considering dutasteride for better results, and maintaining vitamin D levels to protect hair follicles from DHT.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

OP experienced diffuse thinning for 11 years and used Minoxidil and Finasteride previously. They now use Pyrilutamide 0.5% and Alfatradiol 0.1%, resulting in significantly reduced hair loss.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

The user experienced stable hairline but diffuse thinning after switching from oral finasteride to a topical solution of minoxidil and finasteride. They are concerned about the effectiveness of the topical treatment and are considering other options due to a recent decline in hair density.

KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.

PP405 shows potential for hair growth, with 31% of advanced balding men experiencing over 20% increase in hair density in 8 weeks. However, skepticism persists due to selective data presentation and lack of long-term results, with comparisons to treatments like minoxidil and finasteride.

A 25-year-old with AGA experienced hair thinning and dandruff, stabilized with topical finasteride and minoxidil but saw minimal regrowth. They seek advice on styling and consider oral minoxidil and microneedling for denser hair.

Minoxidil-dependent hairs fall out if minoxidil is stopped. New treatments like GT20029, FOL055, or TDM105795 might help sustain these hairs.

A new drug, PP405, is being discussed as a potential cure for baldness, with hopes it could be more effective than Minoxidil and Finasteride. Users are skeptical about its effectiveness and the need for lifelong use.

Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.

Pyrilutamide did not show effectiveness in regrowing hair compared to a placebo, but it may still help maintain existing hair by preventing DHT from causing follicle miniaturization. Some users believe it could be beneficial when used with other treatments like minoxidil, finasteride, and dutasteride.

A 20-year-old female is experiencing hairline loss and seeks effective natural remedies or affordable drugstore treatments. She has tried flax seeds and aloe vera without success.

This conversation discussed the potential for a hair loss treatment alternative to minoxidil, with many users debating the economic and health implications of such an option. Some suggested that finasteride could be used as an alternative, while others argued that this would ultimately not benefit pharmaceutical companies due to their reliance on planned obsolescence.

Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.

The user is concerned about potential alopecia areata. They are seeking advice on whether this condition is normal.

Hair cell therapy and follicle cloning are still in experimental stages, with treatments like hair multiplication and regenerative hair therapy being marketed but not yet proven to create unlimited new follicles. There is skepticism about the effectiveness and legitimacy of these treatments, with some considering them scams.

Minoxidil may suppress androgen activity in hair follicles, potentially aiding in hair growth and prostate cancer treatment. Users discuss the effectiveness of minoxidil and finasteride for hair maintenance and regrowth, with some preferring topical applications over oral due to safety concerns.

The user experienced male pattern baldness starting at 18, tried finasteride with no success, and switched to dutasteride, which halted hair loss. Minoxidil had no effect for them, while their brother, who didn't use AR inhibitors, maintained a juvenile hairline and successfully grew a beard with minoxidil, highlighting the unpredictable nature of genetics in hair loss and treatment response.

The conversation humorously discusses hair loss treatments, mentioning Minoxidil, finasteride, and RU58841. It suggests that affordable genetic therapy could be the ultimate solution.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

A 51-year-old woman switched from Minoxidil to Maneup, a copper peptide treatment, experiencing initial hair loss but later regrowth with different hair texture. Users debated Maneup's effectiveness, with some considering it alongside finasteride.

PP405 shows promise for hair growth but may need continuous use like Minoxidil. Current treatments include Minoxidil, finasteride, and dutasteride, with skepticism about a true cure due to financial interests.

Stopping RU58841 may result in losing only the hair gained from it, unlike stopping Minoxidil, which can lead to losing more hair. The discussion compares the dependency effects of RU58841 and Minoxidil on hair.

User Solid_Repeat5382 shared their experience with Pyrilutamide for hair loss, which initially reduced shedding but later lost effectiveness. They plan to switch back to RU58841 and finasteride, while continuing minoxidil and dermapen treatments.